Asean Business logo
SPONSORED BYUOB logo
SUBSCRIBERS

Medical tourism, biopharma leading the way in China’s healthcare flows to Asean

Patients are flocking to the region in search of good quality, alternative healthcare treatments, while biopharma firms are making forays into new, emerging markets

Megan Cheah
Published Thu, Oct 17, 2024 · 11:04 AM
    • From left: GL Capital partner Wang Yifei; Lepu Medical director Pu Fei; Q&M CEO Ng Chin Siau; Bangkok Dusit Medical Services senior vice-president of international marketing, advertising and public relations Buranut Limjitti; and Etana Biotechnologies chief strategy officer Qi Fei.
    • From left: GL Capital partner Wang Yifei; Lepu Medical director Pu Fei; Q&M CEO Ng Chin Siau; Bangkok Dusit Medical Services senior vice-president of international marketing, advertising and public relations Buranut Limjitti; and Etana Biotechnologies chief strategy officer Qi Fei. PHOTO: CGS INTERNATIONAL

    [HAIKOU] Within the Chinese healthcare sphere, patients and biopharmaceutical companies have something in common – they are increasingly seeing South-east Asia as a key region.

    Patients are flocking to the region in search of good quality, alternative healthcare treatments, while biopharma firms are making forays into new, emerging markets.

    Medical tourism and biopharmaceutical manufacturing are key growth opportunities for companies in China and South-east Asia, as Chinese tourists and biopharma investments flow down to Asean, said healthcare players and observers at a panel discussion in Haikou, China, on Wednesday (Oct 16).

    Copyright SPH Media. All rights reserved.